Imidazole antiproliferative agents

• US 6,201,001 B1
• Filed: 08/02/1999
• Issued: 03/13/2001
• Est. Priority Date: 08/02/1999
• Status: Expired due to Term

• Current Assignee: Abbvie Incorporated
• Original Assignee: Abbott Laboratories
• Inventors: Wang, Le, Sham, Hing L., Woods, Keith W., Li, Qun
• Primary Examiner(s): KRASS, FREDERICK F
• Application Number:
  US09/365,936
• Time in Patent Office: 589 Days
• Field of Search: 514/396, 514/399, 514/400, 548/335.1, 548/335.5, 548/339.5, 548/340.1, 548/341.1, 548/342.5, 548/343.1, 548/343.5
• US Class Current: 514/396
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 233/64 with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Abstract

Compounds of formula I

inhibit celluar proliferation. Processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

Claims

1. A compound selected from the group consisting of

2-methoxy-5-(1-methyl-4-(3,4,5-trimethoxyphenyl)-1H-imidazol-5-yl)phenylamine,

5-(3-fluoro-4-methoxyphenyl)-1-methyl-4-(3,4,5-trimethoxyphenyl)-1H-imidazole, and

N,N-dimethyl-4-(1-methyl-4-(3,4,5-trimethoxyphenyl)-1H-imidazol-5-yl)aniline.

2. A method of inhibiting tubulin polymerization in a mammal in recognized need of such treatment comprising administering to the mammal a therapeutically effective amount of a compound of claim 1.

3. A method of treating cancer in a mammal in recognized need of such treatment comprising administering to the mammal a therapeutically effective amount of a compound of claim 1.

4. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.